IRadimed Corporation — FY2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015; comparisons are with FY2014. The filing does not provide a clear standalone fourth-quarter financial summary. IRadimed develops and sells MRI-compatible infusion pumps, disposables, accessories and services, primarily to hospitals and imaging centers. It reported an estimated global installed base of approximately 3,260 pump systems at year-end.
Financial performance and liquidity
| Metric | FY2015 | FY2014 |
|---|---|---|
| Revenue | $31.6 million | $15.7 million |
| Gross profit / margin | $25.8 million / 81.5% | $12.2 million / 78.3% |
| Operating income / margin | $11.5 million / 36.4% | $3.1 million / 19.6% |
| Net income | $7.5 million | $2.1 million |
| Diluted earnings per share | $0.60 | $0.20 |
| Cash provided by operating activities | $7.6 million | $2.6 million |
| Cash and cash equivalents | $19.4 million | $9.5 million |
| Investments | $7.6 million | $7.9 million |
- Revenue rose 102%, driven mainly by higher pump sales and disposable IV set sales. The company sold 956 pumps versus 536 in 2014; average system selling price increased to approximately $27,500 from $23,800.
- U.S. revenue increased to $28.9 million from $11.4 million; international revenue declined to $2.7 million from $4.3 million. U.S. sales represented approximately 91% of revenue versus 73% in 2014.
- Disposable IV sets and services generated $5.2 million, up from $2.8 million. Management expects these recurring sales to grow as the installed base expands.
- Operating expenses increased to $14.2 million from $9.2 million, but declined as a share of revenue. Income tax expense was $4.1 million; the effective tax rate increased to 35.3% from 32.0%.
- Working capital was $31.1 million and stockholders’ equity was $31.9 million at year-end. The company reported no outstanding debt; its prior uncommitted $100,000 credit facility had been terminated in 2014. Management said available liquidity and expected cash generation should fund projected needs for at least 12 months.
- Cash used in investing activities was $0.1 million, while financing activities provided $2.3 million, principally from option and warrant exercises and related tax benefits. Capital expenditures were $0.3 million.
Material changes, outlook and key risks
- FDA matters: The 2014 FDA Warning Letter concerned quality-system and software validation issues and asserted that changes to earlier pump software required new 510(k) submissions. U.S. distribution resumed under FDA enforcement discretion—first without, then with, the DERS option—but the company had not fully resolved the Warning Letter or completed FDA review of its submission by year-end 2015. Further FDA action could restrict distribution, require corrective action or affect clearances.
- Outlook: Management expected 2016 revenue to increase, citing expansion of the U.S. sales force, greater market awareness and broader hospital use. It planned to launch a new MRI-compatible vital-signs monitor in the second half of 2016. Operating expenses were expected to rise with hiring, product launch costs and depreciation. These are expectations, not guaranteed results.
- Year-end backlog was approximately $13.9 million, but orders could be cancelled or rescheduled; management cautioned that backlog is not a reliable measure of future revenue.
- The business remains highly dependent on its MRidium infusion pump and related disposables. A sole-source supplier provides the core ultrasonic motor, and the company also relies on limited-source components and a single Florida manufacturing facility.
- Other risks include regulatory compliance and product quality, recalls or liability claims, long hospital sales cycles, customer capital-spending constraints, reliance on international distributors and GPO relationships, competition, and dependence on founder and CEO Roger Susi.
- Unusual items included a $55,000 impairment charge for patents related to certain IV sets and $365,000 of medical-device excise tax expense. The federal medical-device excise tax was suspended for 2016 and 2017. The 2013 DERS software recall was closed by the FDA in July 2015; the securities class action and German trademark dispute were resolved.
- After year-end, the board authorized up to $10 million in common-stock repurchases through January 28, 2017. The company reported no cash dividends and did not expect to pay them in the foreseeable future.
Most important facts for investors to verify
- Subsequent FDA decisions, inspection outcomes and any conditions or restrictions on U.S. product distribution.
- Whether 2016 revenue growth and the planned vital-signs monitor launch were achieved, including associated costs and regulatory clearances.
- Revenue quality and sustainability: pump volumes and pricing, recurring disposable and service sales, and the decline in international revenue.
- Backlog conversion, cancellations and customer concentration; confirm that the reported year-end absence of significant receivables concentration continued.
- Continuity of the core motor and other component supplies, manufacturing capacity, and progress toward alternate sources.
- Capital allocation and liquidity effects of the share-repurchase program, alongside cash needs for growth and product development.